Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
Daunorubicin hydrochloride (HB4376)
Description:RNA and DNA synthesis inhibitor. Antibiotic.
Purity:>98%
- Description:
Selective α-mannosidase I inhibitor
Dexamethasone (HB2521)
Description:Anti-inflammatory synthetic glucocorticoid. Induces hMSC differentiation. Apoptosis inducer.
Purity:>98%
Dexamethasone (water-soluble) (HB6020)
Description:Synthetic glucocorticoid with potent anti-inflammatory actions. Induces hMSC differentiation. Apoptosis inducer. Water soluble and suitable for cell culture.Â
Purity:>98%
Diastovaricin I (HB3872)
Description:Antibiotic with antitumor and antibacterial activity
Purity:>98%
- Description:
Potent antiviral compound
Purity:>97%
Disulfiram (HB1119)
Description:Reversibly stimulates SERCA Ca2+-ATPase. V-ATPase inhibitor.
Purity:>97%
Doxorubicin hydrochloride (HB4183)
Description:Antibiotic. DNA topisomerase II inhibitor. Apoptosis inducer.
Purity:>99%